| Literature DB >> 26332375 |
Miriam Cebey-López1, Jethro Herberg2, Jacobo Pardo-Seco3, Alberto Gómez-Carballa3, Nazareth Martinón-Torres1, Antonio Salas4, José María Martinón-Sánchez1, Stuart Gormley2, Edward Sumner5, Colin Fink5, Federico Martinón-Torres1.
Abstract
BACKGROUND: Molecular techniques can often reveal a broader range of pathogens in respiratory infections. We aim to investigate the prevalence and age pattern of viral co-infection in children hospitalized with lower tract acute respiratory infection (LT-ARI), using molecular techniques.Entities:
Mesh:
Year: 2015 PMID: 26332375 PMCID: PMC4558027 DOI: 10.1371/journal.pone.0136526
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
PCR gene targets and sources from which the primers were obtained.
| Virus | Gene targets |
|---|---|
| Influenza A [ | Gene N |
| Influenza B [ | Gene M |
| Metapneumovirus [ | Gene N |
| RSV [ | Gene N |
| Parainfluenza 1 [ | Gene HN |
| Parainfluenza 2 [ | Gene HN |
| Parainfluenza 3 [ | Gene HN |
| Parainfluenza 4 [ | Gene P |
| Rhinovirus [ | 5’ UTR |
| Adenovirus (A-F) [ | Hexon |
| Bocavirus [ | NS encoding region |
| Coronavirus NL63 [ | Gene N |
| Coronavirus 229E [ | Gene M |
| Coronavirus OC43 [ | Gene N |
This multiplex nested PCR was performed in all samples independently of any diagnostic test carried out by the referring hospital.
Distribution of viral agents according to age in the GENDRES cohort (GEN) and UK cohort (UK).
Data are presented as number of positive samples (percentage of evaluated samples) or the mean (standard deviation). Age is expressed in months.
|
|
|
|
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||||||||||
| GEN | UK | GEN | UK | GEN | UK | GEN | UK | GEN | UK | GEN | UK | GEN | UK | GEN | UK | |
| RSV | 108 | 35 | 53 | 21 | 55 | 14 | 8.1 | 12.8 | 88 | 21 | 12 | 8 | 5 | 5 | 3 | 1 |
| (52.9) | (36.1) | (55.8) | (33.3) | (59.8) | (43.8) | (14.9) | (14.6) | (64.7) | (53.8) | (48.0) | (47.1) | (19.2) | (29.4) | (18.8) | (4.2) | |
| Rhinovirus | 68 | 24 | 17 | 11 | 51 | 13 | 14.4 | 40.9 | 44 | 7 | 9 | 5 | 11 | 6 | 3 | 6 |
| (33.3) | (24.7) | (17.9) | (17.5) | (55.4) | (40.6) | (17.4) | (46.3) | (32.4) | (17.9) | (36.0) | (29.4) | (42.3) | (35.3) | (18.8) | (25.0) | |
| Bocavirus | 48 | 19 | 6 | 3 | 42 | 16 | 22.5 | 31.9 | 21 | 4 | 10 | 8 | 13 | 4 | 4 | 3 |
| (23.5) | (19.6) | (6.3) | (4.8) | (45.7) | (50.0) | (27.4) | (35.8) | (15.4) | (10.3) | (40.0) | (47.1) | (50.0) | (23.5) | (25.0) | (12.5) | |
| Adenovirus | 39 | 9 | 4 | 3 | 35 | 6 | 21.4 | 51.2 | 15 | 2 | 11 | 1 | 9 | 3 | 4 | 3 |
| (19.1) | (9.3) | (4.2) | (4.8) | (38.0) | (18.8) | (20.1) | (48.9) | (11.0) | (5.1) | (44.0) | (5.9) | (34.6) | (17.6) | (25.0) | (12.5) | |
| Metapneumovirus | 27 | 4 | 9 | 2 | 18 | 2 | 16.8 | 48.5 | 18 | 1 | 3 | 1 | 5 | 1 | 1 | 1 |
| (13.2) | (4.1) | (9.5) | (3.2) | (19.6) | (6.3) | (27.7) | (57.2) | (13.2) | (2.6) | (12.0) | (5.9) | (19.2) | (5.9) | (6.3) | (4.2) | |
| Influenza virus | 12 | 23 | 4 | 13 | 8 | 10 | 35.7 | 45.9 | 2 | 5 | 4 | 5 | 4 | 5 | 2 | 8 |
| (5.9) | (23.7) | (4.2) | (20.6) | (8.7) | (31.3) | (43.2) | (44.0) | (1.5) | (12.8) | (16.0) | (29.4) | (15.4) | (29.4) | (12.5) | (33.3) | |
| Parainfluenza | 5 | 6 | 1 | 3 | 4 | 3 | 40.4 | 41.6 | 3 | 2 | 0 | 1 | 1 | 2 | 1 | 1 |
| (2.5) | (6.2) | (1.1) | (4.8) | (4.3) | (9.3) | (53.5) | (55.8) | (2.2) | (5.1) | (0.0) | (5.9) | (3.8) | (11.8) | (6.3) | (4.2) | |
| Coronavirus | 5 | _ | 1 | _ | 4 | _ | 25.3 | _ | 2 | _ | 0 | _ | 1 | _ | 1 | _ |
| (2.5) | (1.1) | (4.3) | (23.5) | (1.5) | (0.0) | (3.8) | (6.3) | |||||||||
|
| 92 | 29 | _ | _ | _ | _ | 15.1 | 25.6 | 53 | 8 | 16 | 10 | 18 | 6 | 4 | 4 |
| (45.1) | (29.9) | (16.1) | (25.1) | (41.7) | (23.5) | (72.7) | (66.7) | (75.0) | (35.3) | (30.8) | (21.1) | |||||
|
| 204 | 97 | 95 | 56 | 92 | 29 | 16.7 | 36.6 | 136 | 39 | 25 | 17 | 26 | 17 | 16 | 24 |
| (46.1) | (57.7) | (45.1) | (29.9) | (28.5) | (44.6) | (67.0) | (40.2) | (12.3) | (17.5) | (12.8) | (17.5) | (7.9) | (24.7) | |||
Associations among respiratory pathogens in hospitalized children in the GENDRES and UK cohorts.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
|
|
|
| 65 | 34.2 | 24 | 28.2 |
| RSV+hRV/hBov/AdV/MPV/IV | 23/10/7/2/0 | 12.3/5.3/3.7/1.1/0.0 | 3/4/2/0/2 | 3.5/4.7/2.4/0.0/2.4 |
| hRV+hBov/hCov/AdV/MPV/IV/HPIV | 2/2/6/3/0/0 | 0.5/1.1/3.2/1.6/0.0/0.0 | 3/0/1/1/1/1 | 3.5/0.0/1.2/1.2/1.2/1.2 |
| IV+hBov/MPV | 2/1 | 1.1/0.5 | 5/0 | 5.9/0.0 |
| hBov+AdV/hCov/MPV | 1/1/4 | 0.5/0.5/2.1 | 0/0/0 | 0.0/0.0/0.0 |
| AdV+HPIV/MPV | 1/1 | 0.5/0.5 | 1/0 | 1.2/0.0 |
|
| 21 | 11.3 | 4 | 4.7 |
| RSV+hRV+AdV/hBov/hCov | 3/3/1 | 1.6/1.6/0.5 | 0/0/0 | 0.0/0.0/0.0 |
| RSV+hBov+IV/AdV | 2/4 | 0.5/1.1 | 0/1 | 0.0/1.2 |
| hRV+hBov+AdV/IV | 4/0 | 2.1/0.0 | 1/1 | 1.2/1.2 |
| IV+hBov+AdV | 2 | 1.1 | 1 | 1.2 |
| hBov+MPV+AdV/HPIV | 2/2 | 1.1/1.1 | 0/0 | 0.0/0.0/ |
|
| 6 | 3.2 | 1 | 1.2 |
| hRV+hBov+AdV+IV/MPV/HPIV | 1/3/1 | 0.5/1.6/0.5 | 0 | 0.0 |
| hRV+hBov+MPV+HPIV/RSV | 1/0 | 0.5/0.0 | 0/1 | 0/1.2 |
Fig 1Pathogen prevalence in the main and replication cohorts shown as number detected in nasopharyngeal samples considering the age of the children.
Only the more prevalent viruses are presented.
Virus detection in PICU admitted patients in both cohorts.
No differences were found when compared to those children not requiring PICU admission.
| Virus | GENDRES cohort | UK cohort | ||||
|---|---|---|---|---|---|---|
| PICU admission ( | No PICU admission ( |
| PICU admission ( |
|
| |
|
| 24 (63.2) | 56 (60.2) | 0.844 | 17 (39.5) | 18 (33.3) | 0.671 |
|
| 15 (39.5) | 28 (30.1) | 0.312 | 11 (25.6) | 13 (24.1) | 1.000 |
|
| 6 (15.8) | 21 (22.6) | 0.479 | 7 (16.3) | 12 (22.2) | 0.451 |
|
| 5 (13.2) | 14 (15.1) | 1.000 | 3 (7.0) | 6 (11.1) | 0.727 |
|
| 1 (2.6) | 13 (14.0) | 0.066 | 2 (4.7) | 2 (3.7) | 1.000 |
|
| 1 (2.6) | 4 (4.3) | 1.000 | 8 (18.6) | 15 (27.8) | 0.342 |
|
| 1 (2.6) | 3 (3.2) | 1.000 | 1 (2.3) | 5 (9.3) | 0.223 |
|
| 1 (2.6) | 1 (1.1) | 0.498 | - | - | - |